Biological Relevance: Implemented strategies to understand the pathogenesis of each disease, listing relevant pathways and analyzing target relevance. Each indication was graded based on its role in disease pathogenesis and pathway relevance.

Market Fundamentals: A comparative analysis and landscaping were performed to assess the rationale and calculate relative unmet need scores and sub-scores for each indication.

Commercial Ease: Strategies were developed to estimate the cost to reach clinical proof of concept (POC) based on the average number of patients and cost per patient. Additionally, potential funding sources and bodies were evaluated to support the advancement to Phase 2 clinical trials.